Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Condition(s):Solid Tumor, AdultLast Updated:December 24, 2018Unknown status
Hide Studies Not Open or Pending
Condition(s):Solid Tumor, AdultLast Updated:December 24, 2018Unknown status
Condition(s):Advanced CancerLast Updated:February 5, 2020Completed
Condition(s):Breast Cancer; Prostate Cancer; Advanced Solid TumorsLast Updated:May 6, 2023Completed
Condition(s):Prostate CancerLast Updated:May 5, 2022Completed
Condition(s):Invasive Breast CancerLast Updated:May 4, 2017Completed
Condition(s):Advanced Solid Malignancy; Advanced Solid TumorLast Updated:April 26, 2016Completed
Condition(s):Advanced Solid Malignancy,; Safety and Tolerability,; Pharmacokinetics, Pharmacodynamics,; Tumour Response,Last Updated:May 25, 2016Completed
Condition(s):Advanced Solid Malignancy; Safety and Tolerability; Pharmacokinetics; Pharmacodynamics; Tumour Response; Advanced or Metastatic Breast Cancer; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; PIK3CA; AKT1; PTEN; ER Positive; HER2 PositiveLast Updated:January 22, 2024Active, not recruiting
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:January 3, 2024Active, not recruiting
Condition(s):Advanced Gastric CancerLast Updated:December 30, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.